 COPENHAGEN, Denmark, July 29, 2022 GLOBE NEWSWIRE -- Evaxion Biotech AS NASDAQ: EVAX Evaxion or the Company, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its second-quarter 2022 financial results on August 10 at 8.30 a.m. EDT. 